Phathom posts Q1 net loss $82.9M, revenue $1.9M; VOQUEZNA prescriptions top 17,500

Phathom Pharmaceuticals, Inc.

2024-Q1 EPS reported -$1.42 revenue$1,912,000

Net loss GAAP $82.9M (non-GAAP adj. net loss $64.8M) vs $37.8M loss Q1 2023; revenue $1.9M from VOQUEZNA launch.
Over 17,500 prescriptions dispensed launch-to-date (+361% vs last quarterly report); >3,800 prescribers.
SG&A expenses $62.0M (up from $18.6M YoY) reflecting commercial infrastructure build and marketing.
Cigna added VOQUEZNA to formularies; commercial coverage now ~48% of U.S. commercial lives (~72M covered).
FDA PDUFA date July 19, 2024 for NERD indication; Phase 3 NERD and Phase 2 EoE studies planned later in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Phathom Pharmaceuticals, Inc. reported the first quarter of 2024 results: revenue Net revenues for the first quarter 2024 were $1.9 million, net income Net loss for the first quarter 2024 was $82.9 million.

Period: the first quarter of 2024
Revenue: Net revenues for the first quarter 2024 were $1.9 million
Net income: Net loss for the first quarter 2024 was $82.9 million
Result: reported results

Exact text from the filing

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the first quarter of 2024

View on SEC.gov

1435 earnings releases filed in the last 30 days. Browse all earnings releases →

Phathom Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-134793

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.